Literature DB >> 24584680

5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine.

Xiaojuan Wang1, Yannan Fang, Jianbo Liang, Miansheng Yan, Rong Hu, Xiaoping Pan.   

Abstract

Neurogenic dural vasodilation has been demonstrated to play an important role in migraine. 5-HT(7) receptors have been found on trigeminal nerve endings and middle meningeal arteries and demonstrated involved in the dilatation of meningeal arteries. The aim of the present study was to demonstrate whether 5-HT(7) receptors are involved in neurogenic dural vasodilation in migraine. The neurogenic dural vasodilation model of migraine was used in this study. Unilateral electrical stimulation of dura mater was performed in anesthetized male Sprague-Dawley rats. Animals were pretreated with selective 5-HT(7) receptor agonist AS19, 5-HT(7) receptor antagonist SB269970, 5-HT1B/1D receptor agonist sumatriptan, or vehicles. Blood flow of the middle meningeal artery (MMA) was measured by a laser Doppler flowmetry. AS19 significantly increased the basal and stimulated blood flows of the middle meningeal artery following electrical stimulation of dura mater, and its effect was dose dependent at the early stage. SB269970 and sumatriptan significantly reduced the basal and stimulated blood flows of middle meningeal artery. The present study demonstrates for the first time that 5-HT(7) receptors are involved in neurogenic dural vasodilation evoked by electrical stimulation of dura mater and maybe of relevance in the pathophysiology and treatment of migraine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24584680     DOI: 10.1007/s12031-014-0268-9

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  33 in total

1.  Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy.

Authors:  Marton Graf; Rita Jakus; Sandor Kantor; Gyorgy Levay; Gyorgy Bagdy
Journal:  Neurosci Lett       Date:  2004-04-08       Impact factor: 3.046

Review 2.  Functional, molecular and pharmacological advances in 5-HT7 receptor research.

Authors:  Peter B Hedlund; J Gregor Sutcliffe
Journal:  Trends Pharmacol Sci       Date:  2004-09       Impact factor: 14.819

3.  Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.

Authors:  Anna Wesołowska; Agnieszka Nikiforuk; Katarzyna Stachowicz; Ewa Tatarczyńska
Journal:  Neuropharmacology       Date:  2006-07-07       Impact factor: 5.250

4.  Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies.

Authors:  D J Williamson; R J Hargreaves; R G Hill; S L Shepheard
Journal:  Cephalalgia       Date:  1997-06       Impact factor: 6.292

Review 5.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

6.  Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses.

Authors:  P De Vries; E W Willems; J P Heiligers; C M Villalón; P R Saxena
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  5-HT7 receptor-mediated dilatation in the middle meningeal artery of anesthetized rats.

Authors:  José A Terrón; Esther Martínez-García
Journal:  Eur J Pharmacol       Date:  2007-01-19       Impact factor: 4.432

8.  Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.

Authors:  Robin James Storer; Simon Akerman; Peter J Goadsby
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

10.  Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation.

Authors:  A P Andreou; P R Holland; P J Goadsby
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

View more
  6 in total

1.  5-HT7 Receptors Are Not Involved in Neuropeptide Release in Primary Cultured Rat Trigeminal Ganglion Neurons.

Authors:  Xiaojuan Wang; Rong Hu; Jianbo Liang; Ze Li; Weiwen Sun; Xiaoping Pan
Journal:  J Mol Neurosci       Date:  2016-02-18       Impact factor: 3.444

Review 2.  Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache.

Authors:  Roger Gregory Biringer
Journal:  Mol Cell Biochem       Date:  2022-04-28       Impact factor: 3.842

Review 3.  Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.

Authors:  Agnieszka Nikiforuk
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

4.  Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.

Authors:  Levente Knapp; Bence Szita; Kitti Kocsis; László Vécsei; József Toldi
Journal:  Drug Des Devel Ther       Date:  2016-12-20       Impact factor: 4.162

Review 5.  Advances in Meningeal Immunity.

Authors:  Rejane Rua; Dorian B McGavern
Journal:  Trends Mol Med       Date:  2018-05-03       Impact factor: 11.951

6.  Gi-protein-coupled 5-HT1B/D receptor agonist sumatriptan induces type I hyperalgesic priming.

Authors:  Dioneia Araldi; Luiz F Ferrari; Jon D Levine
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.